Introduction
============

Liver cancer was recently estimated to be the sixth most common cancer and the fourth most common cause of cancer-related deaths worldwide in 2018. Hepatocellular carcinoma (HCC) comprises 75-85% of primary liver cancer [@B1]. Though conventional HCC therapies, including surgical excision, ablation, chemotherapy, and liver transplantation, have been somewhat effective, cancer relapse and metastasis remain its most serious complications. Although molecular agents targeting the signaling mechanisms involved in the progression and recurrence of HCC have been explored [@B2], the long-term prognosis of patients with HCC is still poor. One reason for the limited efficacy of these therapeutic strategies is due to the self-renewal and drug resistance ability of a small number of cancer cells, known as cancer stem cells (CSCs). Thus, to improve outcomes in HCC therapy, it is critical to identify new methods that target both differentiated tumor cells and CSCs [@B3].

Despite initial successful therapy, a small population of CSCs embedded in tumors fuels tumor growth and plays a significant role in cancer relapse and metastasis [@B4]. CSCs, which undergo the aberrant differentiation of progeny cells, were reported to have characteristic surface markers and express stem cell genes [@B5]. Subsets of liver CSCs are phenotypically marked by CD133 [@B6]. Their elevated expression of sex-determining region Y-box 2 (Sox-2) and Octamer-binding transcription factor 4 (Oct-4) is related to stemness [@B7]-[@B9]. The ability of CSCs to form tumor spheroids in non-adhesive cultures *in vitro*, and to induce tumors on serial transplantation into immunodeficient mice, is also a manifestation of their pluripotency [@B10]. A further hallmark of CSCs is a high degree of epithelial-mesenchymal transition (EMT), which has been linked with cancer aggression and drug resistance. EMT activation is also closely related to stemness and therefore exacerbates tumor-initiating potential of CSCs [@B11], [@B12]. Although these two aspects of CSCs may be connected, recent studies indicate that they may occur in parallel via activation through independent pathways [@B13]. Thus, antitumor strategies that emphasize the dual inhibition of stemness and EMT in CSCs, as well as in the differentiated cancer cells, may enhance the ability of antitumor therapy to block tumor recurrence [@B5].

Arsenic trioxide (ATO) has been approved as a first-line treatment in acute promyelocytic leukemia (APL) by the U. S. Food and Drug Administration because of its remarkable ability to induce complete remission [@B14]. ATO has also been reported to be efficacious against other malignant tumor cell lines, such as mammary cancer, prostate carcinoma, and HCC [@B15]. Despite the success of ATO in treating APL, it proved unsatisfactory in treating solid tumors *in vivo* [@B16]. A multicenter phase II clinical trial also reported that ATO monotherapy did not significantly benefit patients with HCC [@B17]. Currently, ATO is approved by the China Food and Drug Administration only for the palliative treatment of patients with HCC. ATO inhibited markers related to stemness and EMT; it downregulated the stem cell marker Sox-2 in glioma cells, induced differentiation of CD133^+^ HCC cells, and inhibited the EMT process in gastric cancer cells [@B18]-[@B20]. However, to our knowledge, so far, no studies have focused on the ability of ATO to inhibit stemness and EMT simultaneously for cancer treatment. Furthermore, ATO has poor bioavailability and apparent adverse reactions, such as liver dysfunction and side effects on skin that restrict its clinical application in treating solid tumors. Thus, exploring novel strategies to reduce off-target effects and improve bioavailability could enhance the treatment of solid tumors.

The emergence of nanomaterials has provided a versatile platform for cancer treatment. Nanotechnology-based drug delivery systems are potent methods for improving drug efficacy and overcoming side effects and other limitations [@B21]. To determine whether nanoparticle-based delivery could improve the efficacy of ATO, we developed ZnAs\@SiO~2~ nanoparticles (NPs) and tested them for their ability to inhibit cell proliferation, tumor growth, and metastasis in cultured tumor cell lines and *in vivo* models of tumor xenografts and metastases. We also evaluated the inhibitory effects of ZnAs\@SiO~2~ NPs on stemness and EMT as well as explored the underlying molecular mechanisms.

Methods
=======

Materials
---------

Tetraethylorthosilicate (TEOS 99.9%), Zinc chloride (ZnCl~2~ 90%), and Arsenic trioxide (As~2~O~3~ 90%) were obtained from Alfa Aesar. Polyoxyethylene nonylphenyl ether (Igepal Co-520, ESI) was purchased from Sigma-Aldrich. Ethanol ammonium hydroxide, cyclohexane, and sodium metasilicate nonahydrate were purchased from Sinopharm Chemical Reagent Co. Ltd (Shanghai, China). 3-(Dimethyl(3-(trimethoxysilyl) propyl)-ammonio) propane-1-sulfonate was purchased from Meryer Chemical Technology Co., Ltd (Shanghai).

Synthesis of ZnAs\@SiO~2~ NPs
-----------------------------

Zinc arsenite (ZnAsOx) NPs were synthesized by a reverse microemulsion method [@B22]. Briefly, 1630 µL of ZnCl~2~ (0.1 M) was mixed with 35 mL cyclohexane (29 Vol% Igepal Co-520) to form homogeneous microemulsions. Subsequently, 0.1 M aqueous ATO (1630 µL pH ∼8) and 1.6 × 10^-2^ M disodium silicate were added to the solvent mixture. After 6 h of reaction at room temperature (RT), 30 µL TEOS and 500 µL ammonia were added to the silica-coated system, and ZnAsOx NPs were encapsulated in the SiO~2~ matrix. The ZnAs\@SiO~2~ NPs were dispersed in phosphate buffered saline (PBS) (pH 7.4) at 37 °C and 20% v/v FBS was added to the mixture with stirring at 37 °C.

Characterization
----------------

Transmission electron microscope (TEM) images were captured by using the JEM-2100 microscope accelerating at the voltage of 200 kV. The Tecnai F20 microscope accelerating at the voltage of 300 kV was employed for the energy-dispersive X-ray (EDX) element mapping and energy dispersive X-ray spectroscopy (EDS). The inductively-coupled plasma atomic emission spectrometry (ICP-AES) was applied for determining the concentration of Zn and As. Briefly, ZnAs\@SiO~2~ samples were determined at a specific wavelength. The concentration of the sample was compared with that of the standard sample. ICP-AES calibration was recorded using the full quantitative model (R^2^ =0.999). Similarly, the inductively coupled plasma mass spectroscopy (ICP-MS) was applied for determining the As concentration of tissues/organs. The Malvern Zetasizernano ZS instrument was used for the dynamic light scattering (DLS) measurements.

Cell culture
------------

Human HCC cell lines Hep3b, HepG2, and Bel7402 were acquired from the American Type Culture Collection (ATCC, Manassas, VA). MHCC97L cell line were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were maintained in Dulbecco\'s Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA) and penicillin (100 IU/mL)/streptomycin (100 µg/mL) in a humidified atmosphere with 5% CO~2~ and 95% air at 37 °C.

Cell viability assay
--------------------

The cell viability was detected using the MTS assay (Promega, WI). 5×10^3^ cells per well were seeded in 96-well plates and cultured for 24h. Subsequently, the cells were incubated with indicated concentrations of PBS, ATO, or ZnAs\@SiO~2~ NPs. A spectrophotometer at 490nm wavelength was used to determine the absorbance. The cell viability was presented as a percentage OD value of the treated cells versus that of the control group. The half-maximal inhibitory concentration (IC~50~) was calculated to quantify the 50% inhibitory effect versus the PBS-treated control. Cell growth curves were depicted according to the OD value at indicated time points.

Colony formation assay
----------------------

After treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 24 h, cells were seeded in 6-well plates at a density of 5×10^2^ cells per well. After culturing for 14 days, cells were washed twice with PBS. Paraformaldehyde was used to fix the cell colonies for 30 minutes. Subsequently, crystal violet was used for staining for another 30 minutes. All assays were performed in triplicates.

Wound healing assay
-------------------

6×10^5^ cells per well were cultured in 6-well plates until the cells reached 90-100% confluency. Wounds were made using a 200 µL pipette tip and cells were rinsed 3 times with PBS. Cells were then incubated with PBS, 5 µM of ATO or ZnAs\@SiO~2~ NPs for 24 h. Wound healing area was photographed and calculated.

Transwell migration and invasion assays
---------------------------------------

Transwell migration and invasion assays were carried out using a 24-well cell culture insert and BD Transwell chambers (BD Biosciences). After 24h incubation with PBS, ATO, or ZnAs\@SiO~2~ NPs, 2×10^4^ suspended in 200 µL DMEM without FBS were plated in the top chamber, and 600 µL DMEM with 10% FBS was added to the lower chamber. After culturing for 24 h, cells of the bottom surface were fixed using paraformaldehyde for 30 min and subsequently stained by crystal violet while cells adhered to the upper surface were removed using cotton swabs. Subsequently, the chambers were rinsed with water and the cells of the undersurface of the chamber were counted in five random fields under the microscope. For Transwell invasion assay, a similar protocol was adopted except that the top Transwell chambers were precoated with diluted Matrigel (BD Biocoat, Bedford, MA) and 5×10^4^ cells suspended in 200 µl DMEM without FBS were plated in the top chamber.

Apoptosis assessment
--------------------

Flow cytometry was used to assess apoptosis of HCC cells after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs at indicated concentrations for 24 h based on staining with the Annexin V/PI Kit (KeyGEN, Nanjing, China). Cells were digested using 0.25% trypsin without EDTA (Gibco BRL, Grand Island, NY), then washed with PBS twice. After staining with Annexin V and propidium iodide, apoptosis assessment was performed by flow cytometry (Beckman Coulter, CA).

Real-time quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------

An RNeasy Mini Kit (Qiagen Germany) was used to isolate total RNA from HCC cells, and cDNA Reverse Transcription Kit (Applied Biosystems) was used for reverse transcription. RT-qPCR was carried out on a BIO-RAD Real-time PCR system with SYBR green mix (Applied Biosystems). Primers were designed and synthesized by Sangon Biotech (Shanghai, China). The primers sequences are listed in Table [S1](#SM0){ref-type="supplementary-material"}.

Western blot analysis
---------------------

Total lysates of HCC cells were prepared, and proteins were extracted after centrifugation. 30 µg proteins of each sample were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted with indicated antibodies. The visualization of protein signals was performed using a chemiluminescence reaction system following the manufacturer\'s recommenddations. Antibody for cleaved PARP, cleaved Caspase-3, CD133, Sox-2, Oct-4, Vimentin, SHP-1, JAK2, STAT3, p-STAT3, and β-Actin were purchased from Cell Signaling Technology (Danvers, MA). Slug, Snail, p-JAK2, and the second antibodies were acquired from Abcam (Cambridge, UK).

Use of IncuCyte ZOOM
--------------------

MHCC97L and Hep3b cells treated with PBS, ATO, or ZnAs\@SiO~2~ NPs were incubated at 37 °C and monitored in the presence of cleaved Caspase-3 dye for 24 h using the IncuCyte ZOOM (Essen BioScience). The fluorescent pictures were automatically obtained across the indicated periods.

Spheroid formation
------------------

2×10^3^ HCC cells treated with PBS, ATO, or ZnAs\@SiO~2~ NPs were cultured for 7 days in low attachment 6-well plates (Corning, NY) with serum-free F12 medium (SFM) containing appropriate amounts of EGF (Sigma-Aldrich; 10 ng/mL), B27 supplement (Invitrogen, Life Technologies, Carlsbad, CA), and insulin (Sigma-Aldrich; 10 mg/mL). Subsequently, a phase contrast microscope was used to record photos of the spheroids, and their number and size were analyzed.

siRNA transfection
------------------

MHCC97L or Hep3b cells were transfected with control or targeted siRNAs (\#1 or \#2) using Lipofectamine 2000 (Invitrogen). Briefly, a mixture of siRNA (100 nM final concentration) and transfection reagents were incubated for 20 min at RT, added to the cells, and incubated for 48 h. Subsequently, cells were harvested and analyzed for RNA and protein expression. The siRNA sequences are listed in Table [S2](#SM0){ref-type="supplementary-material"}.

Hemolysis rate test
-------------------

Hemolysis was tested to determine the blood compatibility of ZnAs\@SiO~2.~ Fresh anticoagulated blood from human volunteers (2 mL) was diluted with 2.5 mL of saline. The ZnAs\@SiO~2~ was prepared in saline and kept at 37 °C for 30 min. The diluted blood (0.2 mL) was added to ZnAs\@SiO~2~. The mixture was kept at 37 °C for 60 min and then centrifuged at 1500 rpm for 10 min. The supernatant was transferred to a 96-well plate where the absorbance was measured at 545 nm. Positive controls consisted of 0.2 mL diluted blood in 10 mL deionized water while negative controls consisted of 0.2 mL diluted blood in 10 mL of saline. Hemolysis rate was calculated as follows: Hemolysis rate = \[(Dt-Dnc) / (Dpc-Dnc)\] × 100%, where Dt, Dnc, and Dpc are the absorbance values of the sample, negative, and positive controls, respectively.

Animal study
------------

All animal experiments were carried according to the Institutional Ethical Guidelines for Animal Experiments of the fifth affiliated hospital of Sun Yat-sen University. *In vivo* tumorigenicity assay was performed by subcutaneous inoculation into the flanks of 4-week old female nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mice.

To investigate the inhibitory effect of ZnAs\@SiO~2~ NPs on HCC cell growth *in vivo*, xenograft tumor model was created in 6 week-old female BALB/c nude mice following the previously described method [@B23], [@B24]. Briefly, 5×10^6^ MHCC97L cells in 100 µL cold PBS were injected subcutaneously into the flanks of nude mice. When the tumors developed to 100 mm^3^, PBS, ATO, or ZnAs\@SiO~2~ NPs were injected into the mice through the tail vein every 3 days. To monitor tumor growth in real-time, bioluminescence images were taken every 3 days as previously described [@B25].

*In vivo* bio-distribution and whole blood circulation analysis
---------------------------------------------------------------

The isolated tissues/organs were excised from mice 24 h post injection, weighed, lysed, and the concentration of As element was analyzed by ICP-MS. For pharmacokinetic analysis, 20 µL blood was sampled at retroorbital locations at the indicated time points post-injection. Subsequently, the blood samples were lysed at room temperature overnight in 500 mL nitrolysis solution (a mixture of concentrated nitric acid and hydrogen peroxide) and the concentration of As element was analyzed by ICP-MS. After comparing to a fully quantitative model, the results were calculated and recorded as the percentage of injected dose per gram (%ID/g) of tissue. The Winnonlin software was used for calculating the half-life and two-compartment was used for fitting.

Immunohistochemistry (IHC) staining
-----------------------------------

The tumor tissue stemness and EMT expression pattern were determined using IHC staining. Sections of the tumor specimens were subjected to rehydration and antigen retrieval followed by incubation with the first antibodies overnight in a humidified atmosphere at 4°C. After washing with PBS 3 times, horseradish peroxidase-conjugated second antibodies (ZSGB, China) were applied for 30 min at RT. The patterns were then detected by staining with 3, 5-diaminobenzidine (DAB) and hematoxylin.

Statistical analysis
--------------------

The data from at least three independent experiments were expressed as n ± SE. Differences between two groups were analyzed by Student\'s t-test while one-way ANOVA was applied for comparison of more than two subgroups. *P* \< 0.05 was adopted as the criterion for statistical significance. All statistical analyses were performed by SPSS 13.0 software.

Results
=======

Synthesis and characterization of ZnAs\@SiO~2~ NPs
--------------------------------------------------

The ZnAs\@SiO~2~ NPs were prepared and functionalized by a reverse microemulsion method, as illustrated in Figure [1](#F1){ref-type="fig"}A. Briefly, we first synthesized ZnAsOx nanocomplexes by precipitating zinc chloride and aqueous ATO in water nanodroplets. Subsequently, we added TEOS to the microemulsion and coated the hollow silicon shell (HSS) on the ZnAsOx NPs *in situ* to form ZnAs\@SiO~2~ core-shell nanostructures. TEM images showed that ZnAs\@SiO~2~ NPs were highly uniform, with a diameter of 35 ± 2 nm (Figure [1](#F1){ref-type="fig"}B). We could observe the ZnAsOx nanocomplexes embedded in the silica shells. DLS analysis indicated that the ZnAsOx\@SiO~2~ NPs were monodisperse in water with a hydrodynamic diameter of 51 ± 3 nm (Figure [1](#F1){ref-type="fig"}C). The increase in hydrodynamic diameter could be attributed to the hydration layer on the surface of the ZnAs\@SiO~2~ NPs. Scanning TEM and EDX element mapping showed that the Zn and As elements were located in the core of the HSS (Figure [1](#F1){ref-type="fig"}D). EDS analysis further confirmed the successful fabrication of ZnAs\@SiO~2~ (Figure [1](#F1){ref-type="fig"}E). To study the ion release efficiency of ZnAs\@SiO~2~ NPs, they were incubated with PBS at pH values of 7.4 (with or without 10% FBS) and 6.4, chosen to represent the physiological pH of the blood and the acidic tumor microenvironment, respectively. Our results showed that the ion release efficiency of the ZnAs\@SiO~2~ NPs at pH 6.4 was much higher than that at pH 7.4 (Figure [1](#F1){ref-type="fig"}F). Also, ZnAs\@SiO~2~ NPs were stable when 10% FBS was added to PBS mimicking the blood environment. These observations indicated that ZnAs\@SiO~2~ NPs could remain stable in the circulation, whereas the weakly acidic tumor microenvironment facilitated their release suggesting that the ZnAs\@SiO~2~ NPs have enhanced antitumor effects while their toxic side effects may be reduced.

ZnAs\@SiO~2~ NPs inhibit proliferation and promote apoptosis of HCC cells*in vitro*
-----------------------------------------------------------------------------------

We tested the cytotoxicity of HSS and Zn ions toward HCC cells prior to investigating the effect of ZnAs\@SiO~2~ NPs. Neither element alone affected the proliferation of MHCC97L and Hep3b cells after incubation for 24 h, even at concentrations up to 160 µM (Figure [S1](#SM0){ref-type="supplementary-material"}). Multiple HCC cell lines were then exposed to ATO or ZnAs\@SiO~2~ NPs for 24 h at various concentrations to compare their antitumor efficacies. The results showed that ZnAs\@SiO~2~ NPs inhibited proliferation to a significantly greater extent than ATO in all cell lines (Figure [2](#F2){ref-type="fig"}A). The half-maximal inhibitory concentrations (IC~50~) for both hepatocyte and HCC cell lines were determined. The IC~50~ values (48 h) showed that ZnAs\@SiO~2~ NPs exhibited more than 2-fold greater inhibitory efficacy than ATO in all four HCC cell lines (Table [1](#T1){ref-type="table"}, Figure [S2](#SM0){ref-type="supplementary-material"}). Also, the cytotoxicity of ZnAs\@SiO~2~ for hepatocyte cell lines MIHA and L02 was lower than that for HCC cell lines (Table [1](#T1){ref-type="table"}). Patient-derived primary hepatocytes and primary HCC cells were also exposed to ATO or ZnAs\@SiO~2~ NPs for 24 h at indicated concentrations. ZnAs\@SiO~2~ NPs were more cytotoxic to primary HCC cells than ATO, while both ATO and ZnAs\@SiO~2~ showed no obvious cytotoxicity to primary hepatocytes (Figure [S3](#SM0){ref-type="supplementary-material"}). These results collectively suggest that ZnAs\@SiO~2~ NPs specifically kill HCC cells sparing normal liver cells. Cell viability assays at various concentrations for up to 72 h of incubation also showed that ZnAs\@SiO~2~ NPs had a higher growth-inhibitory effect on HCC cells than ATO. A trend toward growth inhibition was noted in a time-dependent manner even when cells were incubated with as little as 5 µM of ZnAs\@SiO~2~ NPs, whereas 20 µM of ATO showed a slight growth trend (Figure [S4](#SM0){ref-type="supplementary-material"}). No cytotoxicity was observed at a concentration of 1 µM. Concentrations of ZnAs\@SiO~2~ NPs greater than 5 µM resulted in a high rate of cell death; therefore 5 µM was adopted as the optimal concentration for further experiments. Changes in mRNA levels of *Ki67* and *PCNA*, indicators of proliferation, also confirmed significantly less proliferation after treatment with 5 µM of ZnAs\@SiO~2~ NPs than with ATO (Figure [2](#F2){ref-type="fig"}B) (P\<0.05). Morphological changes were more obvious after ZnAs\@SiO~2~ NPs treatment with changes in both cell density and the spindle shape of the cells (Figure [2](#F2){ref-type="fig"}C). Furthermore, the colony formation assay showed that ATO decreased the colony-forming ability of MHCC97L and Hep3b cells by 60.66 ± 10.26% and 40.83 ± 4.08%, respectively, while ZnAs\@SiO~2~ NPs reduced colony numbers by 84.18 ± 7.36% and 79.17 ± 3.75%, respectively (Figure [2](#F2){ref-type="fig"}D-F).

We examined whether ZnAs\@SiO~2~ NPs induced apoptosis in HCC cells. Flow cytometry analysis demonstrated higher levels of apoptosis after treatment with ZnAs\@SiO~2~ than with ATO (Figures [3](#F3){ref-type="fig"}A-C, S5). Also, compared to ATO, ZnAs\@SiO~2~ treatment significantly elevated the levels of cleaved PARP and cleaved caspase-3 at the indicated time points (Figure [3](#F3){ref-type="fig"}D). Immunofluorescent staining of cleaved caspase-3 was comparable to the results of Western blots showing a significantly higher level of cleaved caspase-3 in both MHCC97L and Hep3b cells after treatment with ZnAs\@SiO~2~ NPs than with ATO (Figure [3](#F3){ref-type="fig"}E, F). Collectively, these results suggest that ZnAs\@SiO~2~ NPs are more efficacious than ATO against HCC cells *in vitro*.

ZnAs\@SiO~2~ NPs inhibit migration and invasion of HCC cells *in vitro*
-----------------------------------------------------------------------

Because the primary cause of treatment failure or recurrence in cancer is metastasis, in which the cells migrate to and invade other tissues, drugs with the ability to inhibit tumor metastasis are highly desirable in treating cancer. Using wound-healing (Figure [4](#F4){ref-type="fig"}A, B) and Transwell assays (Figure [4](#F4){ref-type="fig"}C, D), we compared the effects of ATO and ZnAs\@SiO~2~ NPs at equal concentrations of As (5 µM) on the migration and invasion of HCC cells. ATO decreased the relative healing area of MHCC97L and Hep3b cells by 37.06 ± 7.19% and 34.02 ± 7.18%, respectively, whereas ZnAs\@SiO~2~ NPs reduced the relative healing area by 84.04 ± 2.95% and 94.02 ± 3.26%, respectively (Figure [4](#F4){ref-type="fig"}A, B, E). The Transwell migration assay indicated reduced migration after ATO treatment in both MHCC97L and Hep3b cells by 32.51 ± 7.46% and 21.09 ± 4.92%, respectively whereas ZnAs\@SiO~2~ NPs reduced migration by 56.32 ± 6.06% and 75.08 ± 7.85%, respectively (Figure [4](#F4){ref-type="fig"}C, F). Furthermore, the Transwell invasion assay revealed that in both cell lines, ATO decreased the invasion ratio (49.79 ± 9.72% and 46.18 ± 11.75%, respectively), although ZnAs\@SiO~2~ NPs reduced it more potently (73.82 ± 6.35% and 69.10 ± 6.06%, respectively; Figure [4](#F4){ref-type="fig"}D, G). These observations indicate that ZnAs\@SiO~2~ NPs are better able to inhibit the migration- and invasion-like activities, which are markers of metastatic capacity.

ZnAs\@SiO~2~ NPs inhibit the stemness and EMT of HCC cells *in vitro*
---------------------------------------------------------------------

To determine whether ZnAs\@SiO~2~ NPs affect stemness in HCC cells, a tumor spheroid-formation assay was conducted. The results showed that ZnAs\@SiO~2~ NPs led to a more significant decrease in the ability of HCC cells to initiate tumor spheroid formation in a serial passage in secondary transplantations than ATO (P\<0.05) (Figure [5](#F5){ref-type="fig"}A-D). RT-qPCR and Western blot assays were used to examine the effect of ZnAs\@SiO~2~ NPs on the expression of stemness markers in HCC cells. Results showed that stemness markers, including CD133, Sox-2, and Oct-4, were downregulated at both the mRNA and protein levels significantly more after incubation with ZnAs\@SiO~2~ NPs than with ATO (Figures S6, 5E, 5F). Collectively, these data suggest that ZnAs\@SiO~2~ NPs inhibit stemness in HCC cells.

EMT is a highly dynamic process implicated in various biological processes during which cells do not necessarily exist in \'pure\' epithelial or mesenchymal states. There are cells with mixed features of the two termed as the intermediate cell states (ICSs), which play an important role in EMT, stemness, and tumor metastasis [@B26]. The potency of both ATO and ZnAs\@SiO~2~ may be measured by the dynamic processes rather than one pure state. Therefore, we examined both epithelial and mesenchymal markers to monitor the existence of ICSs. Treatment with ZnAs\@SiO~2~ NPs resulted in reduced mesenchymal and increased epithelial marker expression, as demonstrated by the elevated expression of E-cadherin and decreased expression of Vimentin, Slug, and Snail. In contrast, cells incubated with ATO did not increase the E-cadherin level and seemingly decreased the expression of mesenchymal markers less potently than ZnAs\@SiO~2~ NPs at 24 h (Figures S7, 5G, 5H, S8). These findings suggest that ZnAs\@SiO~2~ NPs inhibit EMT more effectively than ATO by modulating the expression of transition-related genes. However, the inhibitory effect of ATO on Snail and Vimentin at the protein level was not as apparent as that at the mRNA level. The protein levels in cells are balanced by two processes: de novo synthesis and protein degradation. Decreased levels of Snail and Vimentin RNAs were inconsistent with their protein expression and may be the result of increased protein stability. Moreover, protein expression may lag behind the mRNA for a short period and lead to the inconsistency between mRNA and protein level at a given time point.

ZnAs\@SiO~2~ NPs inhibit stemness and EMT through regulating SHP-1/JAK2/STAT3 signaling pathway
-----------------------------------------------------------------------------------------------

Recent studies showed that Janus kinase 2 (JAK2) signal transducer and activator of transcription 3 (STAT3) play a pivotal role in stemness [@B27] and EMT [@B28]. Dephosphorylation of p-JAK2 and p-STAT3 mediated by SH2-containing protein tyrosine phosphatase 1 (SHP-1) can prevent tumor formation and invasion [@B29]. Here we explored whether ZnAs\@SiO~2~ NPs inhibit stemness and EMT through regulation of SHP-1/JAK2/STAT3 signaling pathway. Western blot analysis showed that, compared to ATO, treatment with ZnAs\@SiO~2~ upregulated SHP-1 and downregulated p-JAK2 and p-STAT3 levels, while the expression of total JAK or STAT3 showed no apparent variations between the two treatments (Figure [6](#F6){ref-type="fig"}A). To validate the role of SHP-1/JAK2/STAT3 axis in stemness and EMT, negative control or SHP-1 siRNAs were used. Following transfection, expression of SHP-1 both at mRNA and protein levels showed that siRNA \#1 was more efficient than siRNA \#2 (Figure. S9). We then transfected both MHCC97L and Hep3b cells with SHP-1 siRNA \#1 before treatment with or without 5 µM ZnAs\@SiO~2~ for 24h. The results showed that treatment with si-SHP-1 suppressed SHP-1 and resulted in upregulation of p-JAK and p-STAT3, their inhibition by ZnAs\@SiO~2~ was reversed, and the inhibition of stemness (CD133, Sox-2, and Oct-4) and EMT (E-cadherin, Vimentin, and Snail) was reduced (Figure [6](#F6){ref-type="fig"}B, C). Furthermore, colony formation assay showed the si-SHP-1 reversal of ZnAs\@SiO~2~ effect which was manifested in reduced colony numbers. This effect was also observed in the sphere formation assay in which si-SHP-1 reversed the ZnAs\@SiO~2~-mediated decrease in both the sphere numbers and size (Figure [6](#F6){ref-type="fig"}D-F). Transwell migration and invasion assay also revealed the decreased migration and invasion rate of HCC cells by ZnAs\@SiO~2~ were restored by si-SHP-1 (Figure [6](#F6){ref-type="fig"}G-I). These data suggest that ZnAs\@SiO~2~ NPs inhibit the stemness and EMT of HCC cells through regulation of the SHP-1/JAK2/STAT3 signaling pathway.

We also assessed the clinical significance of SHP-1. The mRNA reads per kilobase of exon model per million of HCC samples from a TCGA public database were selected and analyzed to compare abundances by GraphPad Prism 8 software. The results demonstrated that the level of SHP-1 in phase T1-2 patients was higher than that of phase T3-4 patients, and there was a higher Child-Pugh grading B&C in high SHP-1 group than low SHP-1 group (Figure. 6J). These observations suggested that SHP-1 might be a tumor suppressor of HCC. Regulation of SHP-1 by ZnAs\@SiO~2~ may, therefore, provide a better strategy for treating liver cancer through inhibiting stemness and EMT.

Pharmacokinetics, bio-distribution and blood compatibility of ZnAs\@SiO~2~ NPs *in vivo*
----------------------------------------------------------------------------------------

To study the pharmacokinetic behavior of ZnAs\@SiO~2~ NPs, blood from tumor-bearing mice was sampled at selected time points post-injection and the concentration of arsenic was measured by ICP-MS. The results showed that the blood circulation half-life of ZnAs\@SiO~2~ NPs was significantly increased (28.81 h), more than 2-fold as that of ATO (14.30 h). ZnAs\@SiO~2~ NPs could be retained in the blood at a concentration of 11.05 %ID/g 6 h after injection (Figure [7](#F7){ref-type="fig"}A) which was much higher than that of 6.30 %ID/g for ATO. The significantly higher blood arsenic concentration of ZnAs\@SiO~2~ NPs is likely to improve drug retention in the systemic circulation and facilitate time-dependent drug accumulation at tumor sites through the EPR effect. The bio-distribution of ZnAs\@SiO~2~ in MHCC97L-tumor-bearing mice was measured 24 h after the treatment and showed high accumulation of ZnAs\@SiO~2~ NPs of 6.27 ± 3.25% and 3.05 ± 1.47% in liver and spleen, respectively, which may be due to the phagocytosis of the reticuloendothelial system. Tumor uptake of ZnAs\@SiO~2~ was 14.54 ± 5.27%ID/g compared to free ATO which was 5.92 ± 1.47%ID/g (Figure [7](#F7){ref-type="fig"}B). These results clearly showed that ZnAs\@SiO~2~ could more efficiently accumulate at tumor sites resulting in a higher concentration of ATO-based Nano drugs.

We also assessed systemic toxicity using hematoxylin-eosin (HE) staining (Figure [7](#F7){ref-type="fig"}C), blood index analyses of both biochemical (Figures [7](#F7){ref-type="fig"}D, 7E, S10) and coagulation properties (Figures [7](#F7){ref-type="fig"}F, S11), and M-mode echocardiography for evaluating the left ventricular eject function (LVEF) (Figure [S12](#SM0){ref-type="supplementary-material"}). The results indicated minimal side effects and acceptable biocompatibility of ZnAs\@SiO~2~ NPs. Hemolysis rate of ATO and ZnAs\@SiO~2~ NPs was also tested and found to be below the threshold value of 5% of the positive control even at the concentration of 0.4 mM (Figure [7](#F7){ref-type="fig"}G) indicating good biocompatibility of ZnAs\@SiO~2~ NPs.

ZnAs\@SiO~2~ NPs inhibit tumor initiation, growth, stemness, EMT, and lung metastasis of HCC cells *in vivo*
------------------------------------------------------------------------------------------------------------

Given the *in vitro* effects of ZnAs\@SiO~2~ NPs, we sought to determine whether these results would translate to *in vivo* conditions using a subcutaneous xenograft mouse model. Implanted MHCC97L cells treated with ZnAs\@SiO~2~ NPs for 24 h failed to initiate tumor formation after 6 weeks, whereas implants of 5×10^4^ and 1×10^5^ MHCC97L cells incubated with ATO generated tumors at rates of 12.5% and 37.5%, respectively (Table [2](#T2){ref-type="table"}).

*In vivo* evaluation of the therapeutic effect of ZnAs\@SiO~2~ NPs were performed in a nude mouse xenograft model bearing human HCC tumors. When the tumors reached ∼100 mm^3^, PBS, ATO, or ZnAs\@SiO~2~ NPs were injected intravenously into the mice (2.0 mg As/kg each [@B22], [@B30]) every 3 days from day 0 to day 18 and tumor volume was measured at each time point (Figure [8](#F8){ref-type="fig"}A). Both ATO and ZnAs\@SiO~2~ NPs inhibited tumor growth, whereas tumors in the mice treated with PBS grew rapidly (Figures [8](#F8){ref-type="fig"}B-D, S13). ZnAs\@SiO~2~ NPs delayed tumor growth significantly and more efficiently than ATO by 2.2-fold. This result could be attributed to the prolonged circulation time of the nanodrug ZnAs\@SiO~2,~ its slow release in the neutral environment, and increased release at the tumor site which, together with the EPR effect, resulted in increased drug accumulation at the tumor site. Importantly, the treated mice maintained a consistent weight (Figure [S14](#SM0){ref-type="supplementary-material"}) over the course of the treatment, indicating that the ZnAs\@SiO~2~ NPs had minimal side effects.

To confirm that ZnAs\@SiO~2~ NPs could inhibit metastasis of HCC cells *in vivo*, a lung metastasis animal model was established through tail vein injection. HE staining was used to confirm metastasis to the lungs, and the numbers of metastatic tumors was counted. The results showed that ZnAs\@SiO~2~ NPs decreased the formation of metastatic tumors in the lungs more significantly than ATO (Figure [8](#F8){ref-type="fig"}E, F). These observations indicate that ZnAs\@SiO~2~ NPs have better ability to inhibit metastasis *in vivo*.

We also analyzed the tumor tissues for the expression of stemness and EMT markers. The results showed that ZnAs\@SiO~2~ NPs significantly reduced the expression of CD133, Sox-2, and Oct-4 (Figure [9](#F9){ref-type="fig"}A). Also, following ZnAs\@SiO~2~ NPs treatment, Slug and Vimentin levels were significantly decreased, and E-cadherin was significantly increased (Figure [9](#F9){ref-type="fig"}B). However, ATO treatment failed to elicit such changes. These results suggest that the *in vitro* effects of ZnAs\@SiO~2~ NPs will translate to the *in vivo* situation. Given that SHP-1/JAK2/STAT3 signaling pathway mediates the inhibition of stemness and EMT of ZnAs\@SiO~2~ NPs *in vitro*, we explored the effect of NPs on this pathway*in vivo*. The IHC results of tumor sections confirmed the superior effect of ZnAs\@SiO~2~ NPs on the upregulation of SHP-1 and inhibition of phosphorylation of JAK/STAT3 compared with ATO (Figure [9](#F9){ref-type="fig"}C), which was consistent with their effect on stemness and EMT (Figure [9](#F9){ref-type="fig"}A, B). This cascade effect leads to suppression of tumor initiation, growth, and metastasis.

Discussion
==========

CSCs are believed to be the root cause of recurrence and metastasis [@B31], [@B32]. Stemness and EMT endow CSCs with the ability to disseminate and initiate tumors at secondary sites. Therefore, strategies inhibiting both stemness and EMT may significantly improve treatment outcomes. ATO was used previously as a radical drug for acute promyelocytic leukemia. The inhibition of stemness or EMT by ATO has been reported [@B18]-[@B20], and although its effects on solid tumors were dissatisfactory, it was still recommended as palliative care for HCC treatment.

Nanoparticle delivery systems can reduce side effects and improve efficacy and biocompatibility compared with conventional chemotherapeutic drugs [@B33]. In this study, we successfully synthesized an HSS-coated nanodrug with high uniformity to deliver As to HCC cells. Due to its intrinsic properties and other advantages, including biodegradability, inorganic components, attractive stability, excellent biocompatibility, and a high surface-to-volume ratio, HSS has been employed as a carrier and has achieved high therapeutic efficacy without adverse reactions [@B22], [@B30]. The biodegradation products of silicon NPs are also extremely biocompatible with various tissues [@B34]; furthermore, through renal clearance, they were readily cleared from a mouse model and produced little toxicity *in vivo*. The microemulsion method used in this study involves uniform-size nanoreactors with aqueous core resulting from a specific ratio of the aqueous phase to the surfactant. The confinement of reactants by micelles facilitates the nucleation and growth of inorganic NPs [@B22]. Within this reverse micelle system, it is also feasible to provide an ideal template *in situ* silica coating leading to more uniform sizes, better appearance, and higher drug loading of the ZnAs\@SiO~2~ (Figure [1](#F1){ref-type="fig"}A-C).

Recently, various nanomaterials have been explored to provide new delivery systems to improve the therapeutic effect of cancer treatment. In our study, ZnAs\@SiO~2~ NPs exhibited superior efficacy in inhibiting proliferation (Figures [2](#F2){ref-type="fig"}, S2-4), inducing apoptosis (Figures [3](#F3){ref-type="fig"}, S5), and preventing migration and invasion (Figure [4](#F4){ref-type="fig"}) of HCC cells which may be related to the higher cellular uptake of ZnAs\@SiO~2~ NPs, a function of their nanosize, compared with ATO. NPs exhibit enhanced cancer cell adherence because of their high surface-to-volume ratio and small size.

Stemness and EMT are two fundamental characteristics of CSCs and account for tumor metastasis and recurrence [@B35], [@B36]. Previous experimental studies have shown that stemness and EMT are interconnected via underlying gene regulatory networks [@B37]. However, recent studies suggest that these two traits can be uncoupled [@B13]. Mesenchymal cancer cells can exhibit a low degree of stemness [@B38] and cancer cells with high stemness can also exhibit a low grade of EMT [@B39]. The reduction in the ability of cells to form spheroids (Figure [5](#F5){ref-type="fig"}A-D) and initiate tumors *in vivo* (Table [2](#T2){ref-type="table"}), together with the decrease in stemness markers (Figure [S6](#SM0){ref-type="supplementary-material"}, 5E, 5F), demonstrated that ZnAs\@SiO~2~ NPs inhibited the self-renewal of HCC cells more effectively than ATO. The nanodrug also inhibited the expression of EMT-related markers in the HCC cells more effectively than ATO (Figure [S7](#SM0){ref-type="supplementary-material"}, 5G, 5H, S8). These observations may represent the mechanism underlying the greater efficacy of ZnAs\@SiO~2~ NPs, especially about inhibiting metastatic behavior *in vitro* (Figure [4](#F4){ref-type="fig"}). These results indicate that ZnAs\@SiO~2~ NPs may very effectively kill CSCs in HCC tumors by simultaneously modulating stemness and EMT.

JAK2/STAT3 signaling axis was reported to be closely associated with maintaining stemness of cancer cells [@B40] and regulation of EMT [@B41]. SHP-1 inhibits this signaling pathway through dephosphorylation of JAK2/STAT3 [@B18]. In our study, we explored whether ZnAs\@SiO~2~ NPs inhibit stemness and EMT by regulating SHP-1/JAK2/STAT3 signaling pathway. The results showed that ZnAs\@SiO~2~ promoted SHP-1 and inactivated JAK2/STAT3 more potently than ATO (Figures [6](#F6){ref-type="fig"}A, 9C). Knockdown of SHP-1 reversed the anti-stemness and EMT effects of ZnAs\@SiO~2~ (Figure [6](#F6){ref-type="fig"}B-I). These results suggested that the inhibitory effect of ZnAs\@SiO~2~ on stemness and EMT was mediated by SHP-1/JAK2/STAT3 signaling pathway. The simultaneous modulation of stemness and EMT through SHP-1/JAK2/STAT3 signaling pathway makes ZnAs\@SiO~2~ a potent drug for inhibiting malignant properties of HCC cells. Furthermore, from the analysis of the TCGA database, we found that high levels of SHP-1 transcripts correlated with better TNM staging and Child-Pugh grading in patients with HCC (Figure [6](#F6){ref-type="fig"}J). SHP-1 has also been demonstrated as a tumor suppressor of hepatocarcinogenesis and HCC progression and was proposed as a novel prognostic biomarker and therapeutic target for HCC [@B29]. Therefore, ZnAs\@SiO~2~ may improve the prognosis of HCC by enhancing the expression of SHP-1.

Notably, ZnAs\@SiO~2~ led to the augmented therapeutic efficacy of solid tumors (Figure [8](#F8){ref-type="fig"}B-D), suppressed metastasis nodules (Figure [8](#F8){ref-type="fig"}E, F) as well as inhibited stemness and EMT (Figures [5](#F5){ref-type="fig"}, 9A, 9B). The acidic microenvironment is a feature of most solid tumors. ZnAs\@SiO~2~ NPs were better able to release As at the lower pH value of 6.4 (Figure [1](#F1){ref-type="fig"}F), which mimics the tumor extracellular pH and lysosomal environment. This pH-triggered release behavior of ZnAs\@SiO~2~ was due to the degradation of the core shell of the ZnAsOx complex resulting in accelerated drug release. EPR effect would work concomitantly with this pH-dependent release resulting in considerable enrichment and delivery of ZnAs\@SiO~2~ at the tumor site (Figure [7](#F7){ref-type="fig"}B). This suggests that the therapeutic efficacy of ZnAs\@SiO~2~ NPs would be augmented once it is within the acidic tumor environment. Another reason for the enhanced efficacy of ZnAs\@SiO~2~ NPs was their prolonged circulation time and higher blood concentration (Figure [7](#F7){ref-type="fig"}A) resulting from its slow release at the neutral pH, which may also be responsible for its minimal side effects *in vivo* (Figures [7](#F7){ref-type="fig"}C-G, S10-12) [@B42].

Previous reports suggested that CSCs differentiate only into non-CSCs (NCSCs). However, a recent study showed that NCSCs in the tumor tissue could de-differentiate into new CSCs, thereby regenerating the tumorigenic potential [@B43], [@B44]. CSCs and NCSCs appear to be able to interconvert and maintain a dynamic equilibrium. To date, various CSCs have been selectively targeted with NPs for cancer therapy. However, selectively eliminating CSCs is insufficient in preventing relapse because of the existence of residual NCSCs. Therefore, an effective therapeutic strategy requires not only depleting CSCs but also eradicating NCSCs [@B31]. Targeting CSCs by inhibiting stemness and EMT, as well as NCSCs by ZnAs\@SiO~2~ NPs, may deplete both cell types in HCC effectively, and thus be a significantly more effective treatment for solid tumors and metastasis.

Our study has identified areas that should be pursued in the future to further improve the efficacy of ZnAs\@SiO~2~ NPs. Since NPs can actively target tumor cells, surface modifications of HSS by chemical manipulations may further improve drug delivery and cellular uptake. Despite current advances, drug resistance remains problematic [@B45] requiring the use of combination therapies with synergistic therapeutic efficacy to suppress resistance [@B46]. However, uneven bio-distribution can impair this synergistic interaction. Nanotechnology enables co-delivery of two synergistic drugs by encapsulating them in the same vehicle and resulting in better pharmacokinetics [@B47]. ZnAs\@SiO~2~ NPs can be further developed to co-deliver As with another HCC drug, such as sorafenib, to improve its therapeutic efficacy.

Conclusion
==========

In this study, we synthesized ZnAs\@SiO~2~ NPs using a "one-pot" reverse microemulsion method for As delivery. ZnAs\@SiO~2~ NPs significantly inhibited tumor growth and metastasis of HCC cells. More importantly, by activating the SHP-1/JAK2/STAT3 signaling pathway, ZnAs\@SiO~2~ NPs inhibited stemness and EMT more efficiently than ATO. Thus, this new drug delivery system may hold tremendous potential to improve HCC treatment.
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![**Synthesis and characteristics of ZnAs\@SiO~2~ NPs. (A)** Depiction of ZnAs\@SiO~2~ NPs synthesis. **(B)** TEM image of ZnAs\@SiO~2~ NPs. Scale bar, 50 nm. Insert: the high-magnification TEM image of ZnAs\@SiO~2~ NPs indicating the formation of zinc arsenite nano-complexes (white arrows) in the silica shell. Scale bar, 10 nm. **(C)** DLS profile of ZnAs\@SiO~2~ NPs. **(D)** EDX mapping images of the ZnAs\@SiO~2~ NPs. Scale bar, 1 µm. **(E)** EDS of accumulative ZnAs\@SiO~2~ NPs in the copper mesh. **(F)** Zn and As ions release from HSS at different pH values of 7.4 (with or without 10% FBS) and 6.4 (n = 3).](thnov09p4391g001){#F1}

![**ZnAs\@SiO~2~ NPs inhibit proliferation of HCC cells *in vitro*. (A)** Cell viability of MHCC97L, Hep3b, HepG2, and Bel7402 cells treated with different concentrations of ATO or ZnAs\@SiO~2~ NPs for 24 h (n = 3). **(B)** mRNA levels of proliferation indicators *Ki67* and *PCNA* in MHCC97L and Hep3b cells after treatment with ATO or ZnAs\@SiO~2~ NPs for 24 h.**(C)** Morphology of MHCC97L and Hep3b cells before and after treatment with PBS, ATO or ZnAs\@SiO~2~ NPs for 24 h. Scale bar, 200 µm. **(D)** Colony forming ability of MHCC97L and Hep3b cells after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 24 h. **(E, F)** Quantification of colony formation assay in MHCC97L and Hep3b cells. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4391g002){#F2}

![**ZnAs\@SiO~2~ NPs promote apoptosis in HCC cells *in vitro*. (A)** Apoptosis analysis of MHCC97L and Hep3b cells after treatment with PBS, ATO or ZnAs\@SiO~2~ NPs for 24 h. **(B, C)** Quantification of apoptosis rate of MHCC97L and Hep3b cells after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 24 h. **(D)** Western blots of cleaved PARP and cleaved Caspase-3 after treatment with ATO or ZnAs\@SiO~2~ NPs at indicated time points. **(E, F)** Cleaved Casepase3 immunofluorescent staining after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs at indicated time points in MHCC97L and Hep3b cells. Scale bar, 200 µm. \*\*\*, *P* \< 0.001.](thnov09p4391g003){#F3}

![**ZnAs\@SiO~2~ NPs inhibit the migration and invasion of HCC cells *in vitro*. (A, B)** Wound-healing ability of HCC97L and Hep3b cells after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 24 h. Scale bar, 500 µm. **(C)** Migration and**(D)** invasion of HCC97L and Hep3b cells after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 24 h. Scale bar, 50 µm. Quantification of **(E)** wound-healing, **(F)** migration, and**(G)** invasion of HCC97L and Hep3b cells after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 24 h. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4391g004){#F4}

![**ZnAs\@SiO~2~ NPs inhibit stemness and EMT in HCC cells *in vitro*. (A,B)** Typical images of tumor spheroids forming ability of MHCC97L and Hep3b cells after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 24h. Scale bar, 50 µm.**(C, D)** Quantification of tumor spheroids forming ability of MHCC97L and Hep3b cells after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 24 h. **(E, F)** Protein levels of stemness markers, CD133, Sox-2, and Oct-4, in MHCC97L and Hep3b cells after treatment with ATO or ZnAs\@SiO~2~ NPs at indicated time points. **(G, H)** Protein levels of EMT markers, E-cadherin, Snail, Slug, and Vimentin in MHCC97L and Hep3b cells after treatment with ATO or ZnAs\@SiO~2~ NPs at indicated time points. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4391g005){#F5}

![**ZnAs\@SiO~2~ NPs inhibit stemness and EMT via SHP-1/JAK2/STAT3 signaling pathway. (A)** Protein levels of SHP-1, p-JAK2, JAK2, p-STAT3 and STAT3 in MHCC97L and Hep3b cells after treatment with PBS, ATO or ZnAs\@SiO~2~ NPs for 24 h. **(B)** ZnAs\@SiO~2~ NPs inhibit JAK2/STAT3 mediated by SHP-1. **(C)** ZnAs\@SiO~2~ NPs inhibit stemness and EMT mediated by SHP-1. **(D-I)** Colony formation assay**(D)**, Sphere formation assay **(E)**, Transwell migration assay **(G)** and invasion assay**(H)** of MHCC97L and Hep3b cells after treatment with ZnAs\@SiO~2~ NPs with or without si-SHP-1 and quantification**(F, I)**, Scale bar, 50 µm.**(J)** Data from TCGA public database showing the negative correlation between mRNA levels of SHP-1 and tumor TNM staging and Child-Pugh grading. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4391g006){#F6}

![**Pharmacokinetics, bio-distribution, and blood compatibility *in vivo*. (A)** Circulation curves of ATO and ZnAs\@SiO~2~ NPs in mice by the measurement of As ions. Concentration of As was determined by ICP-MS. (n = 3) **(B)** Bio-distribution of As ions in mice at 24 h after intravenous injection of ATO and ZnAs\@SiO~2~ NPs (n = 3). **(C)** HE-stained images of tissue sections from main organs: liver, lung, heart, kidney, and spleen of the mice after injections of PBS, ATO, or ZnAs\@SiO~2~ NPs for 6 times in 21 days. Scale bar, 50 µm. (**D-F**) Blood analysis of ALT **(D)**, Cr**(E)**, APTT**(F)** after injections of PBS, ATO, or ZnAs\@SiO~2~ NPs for 6 times in 21 days. **(G)** Hemolysis rate of ATO and ZnAs\@SiO~2~ NPs. \*, *P* \< 0.05; \*\*\*, *P* \< 0.001.](thnov09p4391g007){#F7}

![**ZnAs\@SiO~2~ NPs inhibit tumor growth and metastasis*in vivo.* (A)** Schematic diagram of the subcutaneous xenograft model experimental setups. **(B)** Photograph of tumor grafts excised 21 days after injection. **(C)** Tumor growth curves in mice after treatment with PBS, ATO and ZnAsO\@SiO~2~. **(D)** Tumor weight of mice after treatment by PBS, ATO, and ZnAsO\@SiO~2~. **(E, F)** Photographs and histology images of the lung metastasis model after injections of PBS, ATO, or ZnAs\@SiO~2~ NPs for 21 days and quantification. Scale bar, 200 µm. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4391g008){#F8}

![**ZnAs\@SiO~2~ NPs inhibit EMT, stemness and regulate SHP-1/JAK2/STAT3 signaling pathway *in vivo*. (A)** Immunohistochemical staining and quantification of stemness markers, CD133, Sox-2, and Oct-4, in tumor sections after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 21 days. Scale bar, 50 µm. **(B)** Immunohistochemical staining and quantification of EMT markers, E-cadherin, Slug, and Vimentin, in tumor sections after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 21 days. Scale bar, 50 µm.**(C)** Immunohistochemical staining and quantification of SHP-1, p-JAK2, and p-STAT3 in tumor sections after treatment with PBS, ATO, or ZnAs\@SiO~2~ NPs for 21 days. Scale bar, 50 µm. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4391g009){#F9}

###### 

IC~50~ values of hepatocellular cells and HCC cell lines after treatment with ATO or ZnAs\@SiO~2~ NPs for 48 h. Data are expressed as mean ± standard deviation (n=3).

  Cell lines   IC~50\ ATO~ (µM)   IC~50\ ZnAs\@SiO2~ (µM)   IC~50\ ATO~/IC~50\ ZnAs\@SiO2~
  ------------ ------------------ ------------------------- --------------------------------
  MIHA         65.15 ± 5.07       29.71 ± 4.18              2.19
  L02          68.52 ± 6.32       32.43 ± 4.33              2.11
  MHCC97L      9.95 ± 1.01        3.91 ± 0.85               2.54
  Hep3b        10.45 ± 2.16       3.58 ± 0.97               2.92
  HepG2        20.13 ± 2.84       7.91 ± 1.20               2.54
  Bel7402      10.15 ± 1.72       4.34 ± 0.76               2.34

###### 

*In vivo* tumor development experiments of HCC cells after treatment with PBS, WATO or ZnAs\@SiO~2~ NPs for 24 h in NOD-SCID mice.

  Cells          Incidence     Incidence
  -------------- ------------- -------------
  Cell number    100000        50000
  CON            6/8 (75%)     3/8 (37.5%)
  ATO            3/8 (37.5%)   1/8 (12.5%)
  ZnAs\@SiO~2~   0/8 (0%)      0/8 (0%)
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